Inactive Instrument

Biodexa Pharmaceuticals Plc London S.E.

Equities

BDRX

GB00BNGF1L75

Biotechnology & Medical Research

Midatech Pharma delisting and name change approved

March 24, 2023 at 02:18 pm EDT

Midatech Pharma PLC - Cardiff-based R&D biotechnology company focused on improving the bio-delivery and bio-distribution of medicines - Says resolutions put forward at general meeting, including name change, share consolidation and cancellation of AIM listing, approved. Under the consolidation, every 20 shares will be consolidated into one new ordinary share. Adds that ratio of American depositary shares will change to one ADS per five shares, from one ADS per 25 shares previously. Name change to Biodexa Pharmaceuticals PLC, effective on Monday, also approved. Listing of shares on AIM is expected to be cancelled a month from now. Its sole listing will be on Nasdaq.

Current stock price: 0.99 pence

12-month change: down 92%

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Latest news about Biodexa Pharmaceuticals Plc

European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	11:25am	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Apr. 12	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	Apr. 08	MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	Apr. 05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
ADRs End Higher, Aesthetic Medical International Holdings Group Ltd. Climbs 35.5%	Apr. 03	DJ
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Apr. 03	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Apr. 02	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	Apr. 01	MT
ADRs End Lower; NuCana Slides 15%	Mar. 28	DJ
European Equities Close Modestly Higher in Thursday Trading; Data Shows UK Dipped Into Recession in H2 of 2023	Mar. 28	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday	Mar. 28	MT
Biodexa Pharmaceuticals Plc's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers	Mar. 28	CI
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	Mar. 26	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
European Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading	Mar. 19	MT
Certain Stock Options of Biodexa Pharmaceuticals Plc are subject to a Lock-Up Agreement Ending on 19-MAR-2024.	Mar. 18	CI
Certain Ordinary Shares of Biodexa Pharmaceuticals Plc are subject to a Lock-Up Agreement Ending on 19-MAR-2024.	Mar. 18	CI
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading	Mar. 15	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	Mar. 12	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat	Mar. 01	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Feb. 28	MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Tuesday Trading	Feb. 27	MT

Chart Biodexa Pharmaceuticals Plc

Duration

Period

More charts

Company Profile

Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.

Sector

Biotechnology & Medical Research

Calendar

2024-04-25 - Q4 2023 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.13%	103B
REGENERON PHARMACEUTICALS, INC.	+1.80%	96.56B
ARGENX SE	+1.72%	22.61B
BIONTECH SE	-18.19%	21.18B
GENMAB A/S	-4.50%	19.07B
WUXI APPTEC CO., LTD.	-41.75%	16.53B
BEIGENE, LTD.	-25.68%	14.46B
NEUROCRINE BIOSCIENCES, INC.	+0.93%	13.25B
SAREPTA THERAPEUTICS, INC.	+21.63%	11.1B

Bio Therapeutic Drugs